Admera Health Named Best Biotechnology Business of the Year 2026 in the United States
Admera Health has been named Best Biotechnology Business of the Year 2026 | United States in the Global 100 – 2026 awards.
Admera Health, a U.S.-based provider of advanced genomic sequencing, multi-omics, and bioinformatics solutions, has been named Best Biotechnology Business of the Year 2026 in the United States by the Global 100 awards.
“This recognition belongs to every member of our team who shows up each day committed to getting the science right," said Dr. Yun Zhao, CEO of Admera Health. "We built Admera Health around the idea that researchers deserve a true partner, not just a sequencing vendor. Being named Best Biotechnology Business of the Year is a meaningful validation of that approach, and it motivates us to keep raising the bar for scientists across every stage of their research."
The award recognizes Admera Health's position as a full-service genomics and multi-omics partner, supporting research from early discovery through translational studies. The company's technology portfolio spans more than 30 omics capabilities, including single-cell sequencing, spatial transcriptomics, RNA sequencing, whole genome and whole exome sequencing, and PacBio long-read sequencing, paired with integrated bioinformatics support from sample intake through final analysis.
Central to Admera Health's model is its commitment to keeping sample handling, laboratory processing, and data management entirely within the United States, an approach the company believes reduces risk and builds trust for institutions managing sensitive samples or compliance-heavy workflows. That commitment is backed by CLIA certification and CAP accreditation, including a recent re-accreditation from the College of American Pathologists that reinforces the company's ongoing quality oversight.
Admera Health also points to its 2024 acquisition of BioEcho Life Sciences as a step toward strengthening upstream sample quality through its EchoLUTION™ line of nucleic acid extraction and purification products, along with its growing role in translational research initiatives, including a collaboration with Old Dominion University applying artificial intelligence to Alzheimer's research.
Underpinning all of this is a consultative, scientist-to-scientist approach: Admera Health embeds PhD-level scientists into projects from experimental design through interpretation, including a complimentary project consultation for new clients, to help research teams avoid costly missteps and accelerate time to insight.
The Global 100 – 2026 awards recognize organizations across industries for excellence, innovation, and leadership. Admera Health's selection as Best Biotechnology Business of the Year 2026 in the United States affirms its standing among researchers who require dependable, high-quality genomics and multi-omics partnership at scale.